Please Wait
Applying Filters...
menu
    • menu
    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Kikkoman Biochemifa Company advances global health and safety through precision-driven innovation in biotech and food testing.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    An Enquiry

    Menu

    Darovasertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    IDEAYA Biosciences Reveals Positive Phase 2 Results
    IDEAYA Biosciences Reveals Positive Phase 2 Results

    20 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-positive-phase-2-data-for-darovasertib-in-the-neoadjuvant-setting-of-primary-uveal-melanoma-in-a-proffered-paper-oral-presentation-at-esmo-2025-302588310.html

    PR NEWSWIRE
    20 Oct 2025
    Share Share
    IDEAYA Ph2 Combo Shows OS Benefit in Uveal Melanoma at SMR 2025
    IDEAYA Ph2 Combo Shows OS Benefit in Uveal Melanoma at SMR 2025

    20 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-reports-positive-median-overall-survival-data-from-phase-2-trial-of-the-darovasertib-and-crizotinib-combination-in-first-line-metastatic-uveal-melanoma-at-the-2025-society-for-melanoma-research-congress-302588313.html

    PR NEWSWIRE
    20 Oct 2025
    Share Share
    IDEAYA Reveals Phase 2 Data for Darovasertib in Uveal Melanoma
    IDEAYA Reveals Phase 2 Data for Darovasertib in Uveal Melanoma

    08 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-positive-interim-phase-2-data-for-darovasertib-in-the-neoadjuvant-setting-of-primary-uveal-melanoma-302548579.html

    PR NEWSWIRE
    08 Sep 2025
    Share Share
    Servier Commits up To $530 M Into Eye Cancer Deal with Ideaya
    Servier Commits up To $530 M Into Eye Cancer Deal with Ideaya

    03 Sep 2025

    // PRESS RELEASE

    https://ir.ideayabio.com/2025-09-02-Servier-and-IDEAYA-Biosciences-Partner-to-Bring-Darovasertib,-a-Promising-Uveal-Melanoma-Treatment,-to-Patients-Worldwide

    PRESS RELEASE
    03 Sep 2025
    Share Share
    Ideaya Biosciences to Unveil Phase 2 Darovasertib/Crizotinib
    Ideaya Biosciences to Unveil Phase 2 Darovasertib/Crizotinib

    30 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-to-present-first-median-overall-survival-data-from-phase-2-trial-of-the-darovasertib--crizotinib-combination-in-metastatic-uveal-melanoma-at-the-2025-society-for-melanoma-research-congress-302542236.html

    PR NEWSWIRE
    30 Aug 2025
    Share Share
    IDEAYA Announces Phase 2 Darovasertib Trial Presents at ESMO 2025
    IDEAYA Announces Phase 2 Darovasertib Trial Presents at ESMO 2025

    24 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-proffered-paper-oral-presentation-at-esmo-2025-for-phase-2-clinical-trial-of-neoadjuvant-darovasertib-in-primary-uveal-melanoma-302513177.html

    PR NEWSWIRE
    24 Jul 2025
    Share Share